Rare diseases
Investigational molecules
Locations
Back to Germany36 clinical trials in Buxtehude, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)Study of Fianlimab and Cemiplimab for Patients with Untreated Advanced Melanoma
GermanyStudy on the Effectiveness and Safety of Litifilimab for Patients with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy
GermanyStudy Comparing Relatlimab and Nivolumab Combination vs. Nivolumab Alone for Patients with Advanced Melanoma
GermanyStudy of IO102-IO103 and Pembrolizumab for Patients with Advanced Melanoma
GermanyStudy on the Effectiveness and Safety of Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis Using Topical Corticosteroids
GermanyStudy on Pembrolizumab for Patients with High-Risk Stage III Melanoma After Surgery
GermanyStudy on Dose Flexibility of Upadacitinib for Adults with Moderate to Severe Atopic Dermatitis
GermanyStudy Comparing Pembrolizumab and Placebo for Patients with Resected High-Risk Stage II Melanoma
GermanyStudy on the Effects of Briquilimab in Adults with Chronic Spontaneous Urticaria Unresponsive to Antihistamines
GermanyStudy of Pembrolizumab as Additional Treatment for Patients with High-Risk Locally Advanced Cutaneous Squamous Cell Carcinoma After Surgery and Radiation
GermanyStudy on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma
GermanyStudy Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Stage II-IV Melanoma
GermanyThe busiest research cities in the country
What the registry says about research in the country
Clinical trials focusing on moderate to severe atopic dermatitis and plaque psoriasis, evaluating novel treatments including amlitelimab, eblasakimab, and ESK-001. Research aims to assess treatment efficacy and long-term safety profiles.
Multiple studies examining maintenance therapy and dose optimization in chronic skin conditions.
Comprehensive studies evaluating advanced melanoma treatments, including adjuvant immunotherapy trials with pembrolizumab and novel combination therapies. Research focuses on both early-stage and metastatic disease.
Emphasis on developing more effective treatment strategies for high-risk melanoma patients.
Investigating treatments for chronic urticaria, hidradenitis suppurativa, and bullous pemphigoid. Studies evaluate innovative therapies including remibrutinib and dupilumab for these challenging conditions.
Focus on improving treatment outcomes for patients with resistant disease forms.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
